•
Dec 31, 2022

Oscar Health Q4 2022 Earnings Report

Oscar Health's financial performance showed improvement in core operating margins and key metrics.

Key Takeaways

Oscar Health's Q4 2022 results demonstrated significant year-over-year improvement in core operating margins. The company's focus on cost management and administrative efficiency has positioned it well for future profitability.

Membership increased by 93% year-over-year, reaching 1,151,483 members as of December 31, 2022.

The InsuranceCo Combined Ratio improved by approximately 5 points year-over-year.

Oscar Health is introducing its outlook for 2023 with an anticipated InsuranceCo Combined Ratio at or less than 100%.

The company anticipates Direct and Assumed Policy Premiums of $6.4 billion to $6.6 billion for 2023.

Total Revenue
$995M
Previous year: $496M
+100.6%
EPS
-$1.05
Previous year: -$0.95
+10.5%
Medical Loss Ratio
91.6%
Previous year: 97.9%
-6.4%
Gross Profit
$1.04B
Previous year: $520M
+99.4%
Cash and Equivalents
$1.56B
Previous year: $1.1B
+41.2%
Total Assets
$4.53B
Previous year: $3.32B
+36.3%

Oscar Health

Oscar Health

Oscar Health Revenue by Segment

Forward Guidance

The Company is introducing its outlook for 2023 including anticipated Direct and Assumed Policy Premiums of $6.4 billion to $6.6 billion, an InsuranceCo Combined Ratio at or less than 100%, and a significantly improved Adjusted EBITDA loss of ($175) million to ($75) million.

Positive Outlook

  • Direct and Assumed Policy Premiums of $6,400,000 to $6,600,000
  • Medical Loss Ratio of 82% to 84%
  • InsuranceCo Administrative Expense Ratio of 17% to 18%
  • InsuranceCo Adjusted EBITDA of $20,000 to $120,000
  • Adjusted Administrative Expense Ratio of 20.5% to 21.5%

Revenue & Expenses

Visualization of income flow from segment revenue to net income